KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EPS (Basic) (2018 - 2025)

Historic EPS (Basic) for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$0.16.

  • Esperion Therapeutics' EPS (Basic) fell 666.67% to -$0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.54, marking a year-over-year increase of 1290.32%. This contributed to the annual value of -$0.03 for FY2024, which is 9872.39% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' EPS (Basic) is -$0.16, which was down 666.67% from -$0.06 recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' EPS (Basic) registered a high of $0.36 during Q1 2024, and its lowest value of -$3.5 during Q1 2021.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.5 (2023), whereas its average is -$0.87.
  • Per our database at Business Quant, Esperion Therapeutics' EPS (Basic) soared by 14556.96% in 2024 and then crashed by 15833.33% in 2025.
  • Esperion Therapeutics' EPS (Basic) (Quarter) stood at -$2.39 in 2021, then soared by 69.03% to -$0.74 in 2022, then soared by 32.43% to -$0.5 in 2023, then soared by 77.73% to -$0.11 in 2024, then tumbled by 43.7% to -$0.16 in 2025.
  • Its EPS (Basic) was -$0.16 in Q3 2025, compared to -$0.06 in Q2 2025 and -$0.21 in Q1 2025.